Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tango Therapeutics (TNGX) Non Operating Investment Income (2020 - 2024)

Historic Non Operating Investment Income for Tango Therapeutics (TNGX) over the last 5 years, with Q1 2024 value amounting to -$443000.0.

  • Tango Therapeutics' Non Operating Investment Income fell 12945.48% to -$443000.0 in Q1 2024 from the same period last year, while for Mar 2024 it was $1.9 million, marking a year-over-year increase of 6079.4%. This contributed to the annual value of $150000.0 for FY2024, which is 9614.49% down from last year.
  • According to the latest figures from Q1 2024, Tango Therapeutics' Non Operating Investment Income is -$443000.0, which was down 12945.48% from $867000.0 recorded in Q4 2023.
  • In the past 5 years, Tango Therapeutics' Non Operating Investment Income ranged from a high of $1.5 million in Q1 2023 and a low of -$2.6 million during Q1 2022
  • For the 5-year period, Tango Therapeutics' Non Operating Investment Income averaged around -$17866.7, with its median value being -$9000.0 (2020).
  • Per our database at Business Quant, Tango Therapeutics' Non Operating Investment Income tumbled by 1773333.33% in 2022 and then soared by 26424.36% in 2023.
  • Tango Therapeutics' Non Operating Investment Income (Quarter) stood at -$9000.0 in 2020, then tumbled by 8288.89% to -$755000.0 in 2021, then soared by 252.45% to $1.2 million in 2022, then dropped by 24.67% to $867000.0 in 2023, then plummeted by 151.1% to -$443000.0 in 2024.
  • Its Non Operating Investment Income was -$443000.0 in Q1 2024, compared to $867000.0 in Q4 2023 and $836000.0 in Q3 2023.